Form 4: Immunocore CHRO Sells Shares After RSU Vesting

Immunocore Holdings plc's Chief HR Officer, Tina Amber St Leger, sold 1,000 ordinary shares for tax purposes following the vesting of restricted share units.

Summary

• Tina Amber St Leger, Chief HR Officer of Immunocore Holdings plc, reported transactions involving the company's ordinary shares.
• On February 17, 2026, 2,119 ordinary shares were acquired through the vesting of Restricted Share Units (RSUs).
• On February 18, 2026, 1,000 ordinary shares were sold at a weighted average price of $32.35 per share.
• The sale was conducted as a 'sell-to-cover' arrangement to satisfy income tax liabilities incurred from the RSU vesting.
• Following these transactions, Ms. St Leger beneficially owns 1,119 direct ordinary shares and 6,357 direct Restricted Share Units.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The transaction is a routine 'sell-to-cover' for tax purposes following RSU vesting, which is a common and expected occurrence for executive compensation and does not indicate a significant shift in company fundamentals or insider sentiment.

Positives

• The vesting of 2,119 Restricted Share Units indicates continued service and compensation for the Chief HR Officer, aligning executive incentives with company performance.

Negatives

• An insider sale of 1,000 ordinary shares occurred, though it was explicitly for tax purposes related to RSU vesting, which is a common practice.

Future Outlook

The remaining 6,357 Restricted Share Units are expected to vest in three equal annual installments beginning February 17, 2027, subject to the Reporting Person's continuous service.

Industry Context

StockSavvy.ai notes that this transaction is a routine insider filing, common for executives receiving equity compensation. The 'sell-to-cover' mechanism for tax liabilities upon RSU vesting is a standard practice across industries and typically does not signal a change in management's outlook on the company's prospects.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, tax-related insider transaction and not a discretionary sale based on new information.

Next Steps

• Future vesting of the remaining 6,357 Restricted Share Units in three equal annual installments, starting February 17, 2027.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction where the Chief HR Officer sold shares to cover tax liabilities arising from RSU vesting. Such 'sell-to-cover' transactions are common and do not typically provide new fundamental information about the company's performance or future prospects. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Immunocore, IMCR, Form 4, Insider Transaction, Restricted Share Units, RSU, Executive Compensation, Stock Sale, Sell-to-Cover